ArticleJournal of pineal research2012
Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice.
Article in Journal of pineal research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- The Effect and Mechanism of Magnesium Valproate on Methamphetamine-Addicted Rats.Addiction biology · 2025Article
- Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction.Journal of psychopharmacology (Oxford, England) · 2021Article
- Pharmacological Actions of Carbamate Insecticides at Mammalian Melatonin Receptors.The Journal of pharmacology and experimental therapeutics · 2021Article
- Melatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationship.World journal of psychiatry · 2018Review
- Food-induced reinforcement is abrogated by the genetic deletion of the MTBehavioural brain research · 2018Article
- Learned motivation drives circadian physiology in the absence of the master circadian clock.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Update on melatonin receptors: IUPHAR Review 20.British journal of pharmacology · 2016Review
- MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.Annual review of pharmacology and toxicology · 2016Review
- Insights into the Role of the Habenular Circadian Clock in Addiction.Frontiers in psychiatry · 2015Review
- Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice.Physiology & behavior · 2014Article
- Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice.Psychopharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
This study explored the role of the melatonin receptors in methamphetamine (METH)-induced locomotor sensitization during the light and dark phases in C3H/HeN mice with genetic deletion of the MT(1) and/or MT(2) melatonin receptors. Six daily treatments with METH (1.2 mg/kg, i.p.) in a novel environment during the light phase led to the development of locomotor sensitization in wild-type (WT), MT(1)KO and MT(2)KO mice. Following four full days of abstinence, METH challenge (1.2 mg/kg, i.p.) triggered the expression of locomotor sensitization in METH-pretreated but not in vehicle (VEH)-pretreated mice. In MT(1)/MT(2)KO mice, the development of sensitization during the light phase was significantly reduced and the expression of sensitization was completely abrogated upon METH challenge. During the dark phase the development of locomotor sensitization in METH-pretreated WT, MT(1)KO and MT(2)KO mice was statistically different from VEH-treated controls. However, WT and MT(2)KO, but not MT(1)KO mice receiving repeated VEH pretreatments during the dark phase expressed a sensitized response to METH challenge that is of an identical magnitude to that observed upon 6 days of METH pretreatment. We conclude that exposure to a novel environment during the dark phase, but not during the light phase, facilitated the expression of sensitization to a METH challenge in a manner dependent on MT(1) melatonin receptor activation by endogenous melatonin. We suggest that MT(1) and MT(2) melatonin receptors are potential targets for pharmacotherapeutic intervention in METH abusers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.